We serve Chemical Name:2,3-Diaminonaphthalene CAS:771-97-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,3-Diaminonaphthalene
CAS.NO:771-97-1
Synonyms:2,3-Naphthalenediamine;naphthalene-2,3-diamine;2,3-Diaminonaphthalene;EINECS 212-241-0;MFCD00004116
Molecular Formula:C10H10N2
Molecular Weight:158.200
HS Code:2921590090
Physical and Chemical Properties:
Melting point:197-203 °C
Boiling point:370.6±15.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.757
PSA:52.04000
Exact Mass:158.084396
LogP:1.28
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:2811
Packing Group:
Contact us for information like 2,3-Naphthalenediamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00004116 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 212-241-0 Use and application,EINECS 212-241-0 technical grade,usp/ep/jp grade.
Related News: The FDA regulates cosmetics, but the cosmetics industry itself is responsible for assessing the health and safety of ingredient, and there’s not much FDA oversight of that process,” Bruton said.
The Personal Care Products Council, which represents the cosmetics industry, did not have comment on the findings.
A new study finds that many mass shooters in America suffered from a mental illness that wasn’t being treated when they committed their crime.
“Without losing sight of the larger perspective that most who are violent are not mentally ill, and most of the mentally ill are not violent, our message is that mental health providers, lawyers and the public should be made aware that some unmedicated patients do pose an increased risk of violence,” wrote researchers led by Dr. Ira Glick, from Stanford University’s School of Medicine.
Glick’s team studied 35 mass shooting cases that occurred in the United States between 1982 and 2019 and involved shooters who survived and were brought to trial.
Analysis of various sources of medical evidence on the mass shooters showed that 28 had mental illness diagnoses. Eighteen had schizophrenia and 10 had other diagnoses including bipolar disorder, delusional disorder, personality disorders and substance-related disorders.
Of the 28 shooters with a mental illness diagnosis, none were medicated or received other treatment for their disorders prior to their crimes, according to the study published recently in the Journal of Clinical Psychopharmacology.
Glick and his colleagues also examined 20 mass shooters who died at the crime scene and found that eight had schizophrenia, seven had other mental health diagnoses, and five had unknown diagnoses. None were receiving appropriate medications.
The investigators pointed out that despite the high frequency of mass shooting events in the United States, there has been almost no medical research on the nature and incidence of mental illness among people who commit these crimes.
“The psychiatric disorders seen in perpetrators of mass shootings are serious brain illnesses — as much in need of proper diagnosis and treatment as heart disease or any other medical condition,” the authors noted in a Stanford news release.
“We need to reduce the stigma associated with these diseases to enable patients to receive appropriate and adequate psychiatric medication and other treatments,” they added, “by actually talking to patients and their significant others, we have the opportunity to save lives. 2,3-Diaminonaphthalene manufacturer First up is Lilly, which reached all-time highs this week as attention turned to its once highly hyped donanemab, another anti-amyloid that saw a mixed bag of data back in March, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s. 2,3-Diaminonaphthalene supplier The FDA regulates cosmetics, but the cosmetics industry itself is responsible for assessing the health and safety of ingredient, and there’s not much FDA oversight of that process,” Bruton said.
The Personal Care Products Council, which represents the cosmetics industry, did not have comment on the findings.
A new study finds that many mass shooters in America suffered from a mental illness that wasn’t being treated when they committed their crime.
“Without losing sight of the larger perspective that most who are violent are not mentally ill, and most of the mentally ill are not violent, our message is that mental health providers, lawyers and the public should be made aware that some unmedicated patients do pose an increased risk of violence,” wrote researchers led by Dr. Ira Glick, from Stanford University’s School of Medicine.
Glick’s team studied 35 mass shooting cases that occurred in the United States between 1982 and 2019 and involved shooters who survived and were brought to trial.
Analysis of various sources of medical evidence on the mass shooters showed that 28 had mental illness diagnoses. Eighteen had schizophrenia and 10 had other diagnoses including bipolar disorder, delusional disorder, personality disorders and substance-related disorders.
Of the 28 shooters with a mental illness diagnosis, none were medicated or received other treatment for their disorders prior to their crimes, according to the study published recently in the Journal of Clinical Psychopharmacology.
Glick and his colleagues also examined 20 mass shooters who died at the crime scene and found that eight had schizophrenia, seven had other mental health diagnoses, and five had unknown diagnoses. None were receiving appropriate medications.
The investigators pointed out that despite the high frequency of mass shooting events in the United States, there has been almost no medical research on the nature and incidence of mental illness among people who commit these crimes.
“The psychiatric disorders seen in perpetrators of mass shootings are serious brain illnesses — as much in need of proper diagnosis and treatment as heart disease or any other medical condition,” the authors noted in a Stanford news release.
“We need to reduce the stigma associated with these diseases to enable patients to receive appropriate and adequate psychiatric medication and other treatments,” they added, “by actually talking to patients and their significant others, we have the opportunity to save lives. 2,3-Diaminonaphthalene vendor Catalent��s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management. 2,3-Diaminonaphthalene factory Catalent��s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management.
The Personal Care Products Council, which represents the cosmetics industry, did not have comment on the findings.
A new study finds that many mass shooters in America suffered from a mental illness that wasn’t being treated when they committed their crime.
“Without losing sight of the larger perspective that most who are violent are not mentally ill, and most of the mentally ill are not violent, our message is that mental health providers, lawyers and the public should be made aware that some unmedicated patients do pose an increased risk of violence,” wrote researchers led by Dr. Ira Glick, from Stanford University’s School of Medicine.
Glick’s team studied 35 mass shooting cases that occurred in the United States between 1982 and 2019 and involved shooters who survived and were brought to trial.
Analysis of various sources of medical evidence on the mass shooters showed that 28 had mental illness diagnoses. Eighteen had schizophrenia and 10 had other diagnoses including bipolar disorder, delusional disorder, personality disorders and substance-related disorders.
Of the 28 shooters with a mental illness diagnosis, none were medicated or received other treatment for their disorders prior to their crimes, according to the study published recently in the Journal of Clinical Psychopharmacology.
Glick and his colleagues also examined 20 mass shooters who died at the crime scene and found that eight had schizophrenia, seven had other mental health diagnoses, and five had unknown diagnoses. None were receiving appropriate medications.
The investigators pointed out that despite the high frequency of mass shooting events in the United States, there has been almost no medical research on the nature and incidence of mental illness among people who commit these crimes.
“The psychiatric disorders seen in perpetrators of mass shootings are serious brain illnesses — as much in need of proper diagnosis and treatment as heart disease or any other medical condition,” the authors noted in a Stanford news release.
“We need to reduce the stigma associated with these diseases to enable patients to receive appropriate and adequate psychiatric medication and other treatments,” they added, “by actually talking to patients and their significant others, we have the opportunity to save lives. 2,3-Diaminonaphthalene manufacturer First up is Lilly, which reached all-time highs this week as attention turned to its once highly hyped donanemab, another anti-amyloid that saw a mixed bag of data back in March, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s. 2,3-Diaminonaphthalene supplier The FDA regulates cosmetics, but the cosmetics industry itself is responsible for assessing the health and safety of ingredient, and there’s not much FDA oversight of that process,” Bruton said.
The Personal Care Products Council, which represents the cosmetics industry, did not have comment on the findings.
A new study finds that many mass shooters in America suffered from a mental illness that wasn’t being treated when they committed their crime.
“Without losing sight of the larger perspective that most who are violent are not mentally ill, and most of the mentally ill are not violent, our message is that mental health providers, lawyers and the public should be made aware that some unmedicated patients do pose an increased risk of violence,” wrote researchers led by Dr. Ira Glick, from Stanford University’s School of Medicine.
Glick’s team studied 35 mass shooting cases that occurred in the United States between 1982 and 2019 and involved shooters who survived and were brought to trial.
Analysis of various sources of medical evidence on the mass shooters showed that 28 had mental illness diagnoses. Eighteen had schizophrenia and 10 had other diagnoses including bipolar disorder, delusional disorder, personality disorders and substance-related disorders.
Of the 28 shooters with a mental illness diagnosis, none were medicated or received other treatment for their disorders prior to their crimes, according to the study published recently in the Journal of Clinical Psychopharmacology.
Glick and his colleagues also examined 20 mass shooters who died at the crime scene and found that eight had schizophrenia, seven had other mental health diagnoses, and five had unknown diagnoses. None were receiving appropriate medications.
The investigators pointed out that despite the high frequency of mass shooting events in the United States, there has been almost no medical research on the nature and incidence of mental illness among people who commit these crimes.
“The psychiatric disorders seen in perpetrators of mass shootings are serious brain illnesses — as much in need of proper diagnosis and treatment as heart disease or any other medical condition,” the authors noted in a Stanford news release.
“We need to reduce the stigma associated with these diseases to enable patients to receive appropriate and adequate psychiatric medication and other treatments,” they added, “by actually talking to patients and their significant others, we have the opportunity to save lives. 2,3-Diaminonaphthalene vendor Catalent��s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management. 2,3-Diaminonaphthalene factory Catalent��s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management.
